U.S. panel to consider approval of Roche's Actemra in July

06/5/2008 | Reuters

The FDA's Arthritis Advisory Committee is scheduled on July 29 to review Roche Holding's Actemra for approval. The company believes that the drug, which has been approved in Japan, will gain competitive advantage as an alternative to anti-tumor necrosis factor drugs used in rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC